Brazil vs Iran: The number of people with susceptibility test result for rifampicin
Brazil
50.47
in 2021
Iran
46.76
in 2021
Brazil rank
114th
Iran rank
116th
The number of people with susceptibility test result for rifampicin over time
- Brazil
- Iran
How they compare
Brazil currently reports 50.47 against 46.76 in Iran, a difference of 3.71.
That makes Brazil's figure about 1.1 times Iran's.
The two have swapped places 1 time across 5 shared years of data; in 2017 it was Iran ahead.
Brazil ranks 114th and Iran ranks 116th of 146 countries.
Across the 2 decades both report, Brazil averaged higher in 1 and Iran in 1.
Head to head by decade
| Decade | Brazil | Iran | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 41.74 | 64 | 22.26 | Iran |
| 2020s | 51.96 | 45.93 | 6.03 | Brazil |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher the number of people with susceptibility test result for rifampicin, Brazil or Iran?
- Brazil, at 50.47 against 46.76 in Iran as of 2021.
- What is the difference in the number of people with susceptibility test result for rifampicin between Brazil and Iran?
- 3.71, with Brazil ahead.
- How many years of comparable data are there for Brazil and Iran?
- 5 years are reported by both, from 2017 to 2021.
- How do Brazil and Iran rank globally for the number of people with susceptibility test result for rifampicin?
- Brazil ranks 114th and Iran ranks 116th of 146 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.. Statizoid refreshes it automatically from the source and publishes the full history for both places.